Company intelligence / Profile preview

Sugen Inc.

South San Francisco, California, United Statessugenlife.com ↗
Ownership
Private
Development stage
Other
01

Overview

Sugen was a trailblazer in developing small-molecule tyrosine kinase inhibitors for cancer therapy but did not bring an FDA-approved drug to market before its acquisition[6]. Its research laid the groundwork for later successful drugs in this class[6].

Therapeutic areas
Oncology
Modalities
Small molecules (notably tyrosine kinase inhibitors)
Industry
Biotech
02

Partnerships

AstraZeneca held a significant stake pre-acquisition[1]

Beyond the preview

Go deeper on Sugen Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sugen Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call